Open Access

Profiles of m6A RNA methylation regulators for the prognosis of hepatocellular carcinoma

  • Authors:
    • Wang Li
    • Qi‑Feng Chen
    • Tao Huang
    • Lujun Shen
    • Zi‑Lin Huang
    • Peihong Wu
  • View Affiliations

  • Published online on: March 3, 2020     https://doi.org/10.3892/ol.2020.11435
  • Pages: 3296-3306
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

N6‑methyladenosine (m6A) RNA methylation, which is related to cancer initiation and progression, is dynamically regulated by the m6A RNA methylation regulators (including ‘writers’, ‘erasers’ and ‘readers’). However, the prognostic value of m6A RNA methylation regulators involved in hepatocellular carcinoma (HCC) carcinogenesis and progression remains to be elucidated. The aim of the present study was to determine the prognostic score in predicting the prognosis of HCC patients based on these regulators. In The Cancer Genome Atlas, most of the 13 major m6A RNA methylation regulators were found to be differentially expressed between HCC and normal samples (P<0.001). In addition, two subgroups (clusters 1/2) had also been identified by applying consensus clustering in the m6A RNA methylation regulators. As compared with the cluster 1 subgroup, the cluster 2 subgroup was correlated with a poorer prognosis, as shown by the Kaplan‑Meier method (P=6.197e‑4). A risk signature was constructed based on these findings using six m6A RNA methylation regulators, which could not only predict the clinicopathological features of HCCs, but also serve as an independent prognostic marker, as shown by Cox regression analysis (hazard ratio=1.219, 95% confidence interval: 1.143‑1.299; P<0.001). Data from the International Cancer Genome Consortium were used for external validation. In addition, gene set enrichment analysis identified several pathways that m6A RNA methylation regulators were closely associated with. In conclusion, the m6A RNA methylation regulators are the crucial participants in the malignant progression of HCCs, which are potentially useful for prognosis stratification and therapeutic strategy development for HCC.
View Figures
View References

Related Articles

Journal Cover

April-2020
Volume 19 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li W, Chen QF, Huang T, Shen L, Huang ZL and Wu P: Profiles of m6A RNA methylation regulators for the prognosis of hepatocellular carcinoma. Oncol Lett 19: 3296-3306, 2020
APA
Li, W., Chen, Q., Huang, T., Shen, L., Huang, Z., & Wu, P. (2020). Profiles of m6A RNA methylation regulators for the prognosis of hepatocellular carcinoma. Oncology Letters, 19, 3296-3306. https://doi.org/10.3892/ol.2020.11435
MLA
Li, W., Chen, Q., Huang, T., Shen, L., Huang, Z., Wu, P."Profiles of m6A RNA methylation regulators for the prognosis of hepatocellular carcinoma". Oncology Letters 19.4 (2020): 3296-3306.
Chicago
Li, W., Chen, Q., Huang, T., Shen, L., Huang, Z., Wu, P."Profiles of m6A RNA methylation regulators for the prognosis of hepatocellular carcinoma". Oncology Letters 19, no. 4 (2020): 3296-3306. https://doi.org/10.3892/ol.2020.11435